Curis Inc. buy melinda
Start price
30.08.18
/
50%
€1.36
Target price
20.09.18
€1.89
Performance (%)
10.08%
End price
20.09.18
€1.50
Summary
This prediction ended on 20.09.18 with a price of €1.50. The prediction had a final performance of 10.08%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Curis Inc. | - | - | - | - |
iShares Core DAX® | 1.776% | 3.175% | 14.882% | 17.660% |
iShares Nasdaq 100 | -1.037% | 1.869% | 35.463% | 52.324% |
iShares Nikkei 225® | -0.335% | 3.857% | 14.485% | 11.459% |
iShares S&P 500 | 0.854% | 2.567% | 31.105% | 47.441% |
Comments by melinda for this prediction
In the thread Curis Inc. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 07/11 Publication de résultats
Operates as a drug company
Curis, Inc. is a biotechnology company, which is focused on the development and commercialization of drug candidates for the treatment of human cancers.
Its pipeline includes CUDC-907, CA-170, and CA-327.
The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes.
The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints.
The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Curis, Inc. is a biotechnology company, which is focused on the development and commercialization of drug candidates for the treatment of human cancers.
Its pipeline includes CUDC-907, CA-170, and CA-327.
The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes.
The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints.
The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Nombre d'employés : 55 personnes.
(Vom Mitglied beendet)